Roche to buy metabolic biotech 89bio for up to $3.5B

Roche agreed to buy 89bio, a metabolic disease biotech, for up to $3.5 billion as the Swiss pharma giant builds up its obesity portfolio.

Why it matters: The deal shows Big Pharma values differentiated treatments addressing broader metabolic disease, even in a crowded market.